GT Biopharma Management
Management criteria checks 3/4
GT Biopharma's CEO is Michael Breen, appointed in Mar 2022, has a tenure of 2.17 years. total yearly compensation is $1.89M, comprised of 26% salary and 74% bonuses, including company stock and options. directly owns 2.07% of the company’s shares, worth €80.35K. The average tenure of the management team and the board of directors is 2.3 years and 3.4 years respectively.
Key information
Michael Breen
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 26.0% |
| CEO tenure | 2.2yrs |
| CEO ownership | 2.1% |
| Management average tenure | 2.3yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$15m |
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$2m | US$493k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$3m | US$63k | -US$58m |
Compensation vs Market: Michael's total compensation ($USD1.89M) is above average for companies of similar size in the German market ($USD400.67K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Breen (60 yo)
2.2yrs
Tenure
US$1,892,293
Compensation
Mr. Michael Martin Breen serves as Interim Chief Executive Officer at GT Biopharma, Inc. since March 02, 2022. Mr. Breen serves as an Executive Chairman at GT Biopharma, Inc. since November 08, 2021 and se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Executive Chairman | 2.2yrs | US$1.89m | 2.07% € 80.3k | |
| CFO & Secretary | 2.3yrs | US$993.38k | 0.85% € 32.8k | |
| Consulting Chief Scientific Officer | 4.8yrs | no data | no data |
2.3yrs
Average Tenure
Experienced Management: OXIA's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Executive Chairman | 3.3yrs | US$1.89m | 2.07% € 80.3k | |
| Consulting Chief Scientific Officer | 6.7yrs | no data | no data | |
| Independent Director | 1yr | no data | 0% € 0 | |
| Independent Director | 3.3yrs | US$1.35m | 0% € 0 | |
| Independent Vice Chairman | 3.5yrs | US$548.71k | 0.85% € 33.1k | |
| Scientific Advisor | no data | no data | no data | |
| Chairman of Science Advisory Board | 3.6yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 3.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data |
3.4yrs
Average Tenure
73.5yo
Average Age
Experienced Board: OXIA's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/01 01:03 |
| End of Day Share Price | 2024/02/02 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GT Biopharma, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Walsh | B. Riley Securities, Inc. |
| Charles Butler | Roth Capital Partners |
| Jonathan Aschoff | Roth Capital Partners |